The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2023 | Novel immunotherapies for multiple myeloma & other exciting developments
Wee Joo Chng, MB ChB, MRCP, MRCPath, PhD, National University of Singapore, Singapore, provides an overview of the latest updates in immunotherapies for multiple myeloma. The development of bispecific antibodies and T-cell engagers targeting BCMA and GPRC5D will potentially give patients more treatment options. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
